Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease: A Case–Control Study
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146712 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ioulia Mavrikou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hematology & BMT Unit, General Hospital "George Papanikolaou", 57010 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Hepatic Veno-Occlusive Disease, Genetic Predisposition to Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jazz Pharmaceuticals.
Abstract (Originalsprache)
Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease (SOS/VOD) is a severe complication of hematopoietic cell transplantation (HCT). Furthermore, emerging evidence suggests the potential role of complement activation and endothelial injury in SOS/VOD pathogenesis. In this study, we aimed to identify potential distinct pathogenic genetic variants between SOS/VOD and other endothelial injury syndromes following HCT, such as transplant-associated thrombotic microangiopathy (TA-TMA). For this aim, genomic DNA from 30 SOS/VOD patients and 30 controls with TA-TMA was analyzed. Using Next-Generation Sequencing (NGS), variants in complement-related genes (CFH, CFI, CFB, CFD, C3, CD55, C5, CD46, and thrombomodulin/THBD) and ADAMTS13 were examined. Out of 426 detected variants, 20 were classified as pathogenic. In SOS/VOD patients, variants were identified in ADAMTS13 (4), CFH (3), C3 (2), and CFB (1) genes. One of the variants has been recognized as the strongest genetic predictor of ADAMTS13 activity. Controls exhibited more variants in complement-related genes, particularly CFH, CFI, and C3. The genetic differences between SOS/VOD and TA-TMA highlight different pathogenic mechanisms, offering the potential for targeted risk assessment and therapy in HCT recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology & BMT Unit, General Hospital "George Papanikolaou", 57010 Thessaloniki, Greece.
- Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, 24127 Bergamo, Italy.
- Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
- Microbiology Department, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Department of Haematology and BMT, American Hospital Dubai, Dubai, United Arab Emirates.
ORCID-Profile: Zoi Bousiou, Christos Demosthenous, Paschalis Evangelidis, Eleni Gavriilaki
Förderung
- Jazz Pharmaceuticals
Zitieren
APA
Mavrikou, I., Castelli, M., Touloumenidou, T., Bousiou, Z., Koravou, E. E., Vardi, A., Papalexandri, A., Demosthenous, C., Koutra, M., Evangelidis, P., Panteliadou, A. K., Batsis, I., Chatzidimitriou, D., Nikolousis, E., Rambaldi, A., Sakellari, I., & Gavriilaki, E. (2025). Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease: A Case–Control Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146712
Vancouver
Mavrikou I, Castelli M, Touloumenidou T, Bousiou Z, Koravou EE, Vardi A, et al. Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease: A Case–Control Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146712
BibTeX
@article{Mavrikou2025,
author = {Mavrikou, Ioulia and Castelli, Marta and Touloumenidou, Tasoula and Bousiou, Zoi and Koravou, Evangelia-Evdoxia and Vardi, Anna and Papalexandri, Apostolia and Demosthenous, Christos and Koutra, Maria and Evangelidis, Paschalis and Panteliadou, Alkistis-Kyra and Batsis, Ioannis and Chatzidimitriou, Dimitrios and Nikolousis, Emmanouil and Rambaldi, Alessandro and Sakellari, Ioanna and Gavriilaki, Eleni},
title = {Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease: A Case–Control Study},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146712}
}
EUVIMED